Glenmark Pharmaceuticals Limited

BSE:532296 Stock Report

Market Cap: ₹405.5b

Glenmark Pharmaceuticals Management

Management criteria checks 1/4

Glenmark Pharmaceuticals' CEO is Glenn Saldanha, appointed in Jan 2001, has a tenure of 24.08 years. total yearly compensation is ₹168.61M, comprised of 80% salary and 20% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth ₹1.43B. The average tenure of the management team and the board of directors is 1.8 years and 6.8 years respectively.

Key information

Glenn Saldanha

Chief executive officer

₹168.6m

Total compensation

CEO salary percentage80.0%
CEO tenure24.1yrs
CEO ownership0.4%
Management average tenure1.8yrs
Board average tenure6.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Glenn Saldanha's remuneration changed compared to Glenmark Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-₹10b

Jun 30 2024n/an/a

-₹16b

Mar 31 2024₹169m₹135m

-₹19b

Dec 31 2023n/an/a

-₹8b

Sep 30 2023n/an/a

-₹1b

Jun 30 2023n/an/a

₹3b

Mar 31 2023₹162m₹130m

-₹2b

Dec 31 2022n/an/a

₹9b

Sep 30 2022n/an/a

₹8b

Jun 30 2022n/an/a

₹8b

Mar 31 2022₹158m₹130m

₹9b

Dec 31 2021n/an/a

₹10b

Sep 30 2021n/an/a

₹10b

Jun 30 2021n/an/a

₹10b

Mar 31 2021₹139m₹110m

₹10b

Dec 31 2020n/an/a

₹10b

Sep 30 2020n/an/a

₹9b

Jun 30 2020n/an/a

₹9b

Mar 31 2020₹122m₹91m

₹8b

Dec 31 2019n/an/a

₹7b

Sep 30 2019n/an/a

₹6b

Jun 30 2019n/an/a

₹8b

Mar 31 2019₹157m₹131m

₹9b

Dec 31 2018n/an/a

₹9b

Sep 30 2018n/an/a

₹9b

Jun 30 2018n/an/a

₹7b

Mar 31 2018₹162m₹134m

₹8b

Compensation vs Market: Glenn's total compensation ($USD1.95M) is above average for companies of similar size in the Indian market ($USD572.03K).

Compensation vs Earnings: Glenn's compensation has increased whilst the company is unprofitable.

CEO

Glenn Saldanha (54 yo)

24.1yrs

Tenure

₹168,610,000

Compensation

Mr. Glenn Mario Saldanha has been the Managing Director and Chief Executive Officer of Glenmark Pharmaceuticals Limited since 2000. Mr. Saldanha serves as Chairman at Ichnos Sciences Inc. Mr. Saldanha serv...

Leadership Team

NamePositionTenureCompensationOwnership
Glenn Saldanha
Chairman24.1yrs₹168.61m0.35%
₹ 1.4b
Cherylann Pinto
Executive Director of Corporate Services & Executive Directorno data₹60.84m0.27%
₹ 1.1b
V. Mani
Executive Directorless than a year₹102.12mno data
Harish Kuber
Company Secretary & Compliance Officer8yrs₹5.53mno data
Alind Sharma
President and Chief Human Resources Officer3.1yrsno datano data
Ulhas Dhuppad
President & Head of Global Pharmaceutical Development2.4yrsno datano data
Indrajit Bose
President & Chief Quality Officer1.4yrsno datano data
Brijlal Motwani
President & Global Head of Formulation Operations1.4yrsno datano data
Alok Malik
President & Business Head of India Formulations1.5yrsno datano data
Christoph Stoller
President and Business Head of Europe & Emerging Markets2.1yrsno datano data
Marc Kikuchi
President & Business Head of North Americaless than a yearno datano data
Ravi Agrawal
Investor Relations Officerno datano datano data

1.8yrs

Average Tenure

55yo

Average Age

Experienced Management: 532296's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Glenn Saldanha
Chairman26.3yrs₹168.61m0.35%
₹ 1.4b
Cherylann Pinto
Executive Director of Corporate Services & Executive Director25.3yrs₹60.84m0.27%
₹ 1.1b
V. Mani
Executive Director6.8yrs₹102.12mno data
Cyril Konto
Presidentless than a yearno datano data
Blanche Saldanha
Non Executive Director19.5yrs₹600.00k0.39%
₹ 1.6b
Rajesh Desai
Non-Executive Independent Director22.8yrs₹1.90m0.039%
₹ 156.9m
Vijayalakshmi Iyer
Independent Non-Executive Director2yrs₹1.20mno data
Dipankar Bhattacharjee
Independent Non-Executive Director4.5yrs₹1.10mno data
Sona Saira Ramasastry
Independent Non-Executive Director5.8yrs₹1.40mno data

6.8yrs

Average Tenure

61yo

Average Age

Experienced Board: 532296's board of directors are considered experienced (6.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 20:15
End of Day Share Price 2025/02/01 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Glenmark Pharmaceuticals Limited is covered by 53 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sriraam RathiAnand Rathi Shares and Stock Brokers Limited
null nullAnand Rathi Shares and Stock Brokers Limited
Ganeshram JayaramanAvendus Spark